Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 8/20 | 0.52 |
| ▸ | DRD2 | P14416 | 7/20 | 0.52 |
| ▸ | DRD5 | P21918 | 7/20 | 0.52 |
| ▸ | DRD3 | P35462 | 7/20 | 0.52 |
| ▸ | DRD4 | P21917 | 5/20 | 0.52 |
| ▸ | METAP1 | P53582 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL228868 | 0.93 | DRD1 (0.56) | DRD1DRD2DRD5DRD3DRD4 | |
| SCHEMBL14172824 | 0.90 | DRD1 (0.56) | DRD1DRD2DRD5DRD3DRD4 | |
| SCHEMBL43307 | 0.89 | METAP1 (0.53) | DRD1DRD2DRD5DRD3DRD4 | |
| SCHEMBL29940518 | 0.89 | METAP1 (0.53) | DRD1DRD2DRD5DRD3DRD4 | |
| SCHEMBL4041676 | 0.83 | METAP1 (0.58) | DRD1DRD2DRD5DRD3DRD4 | |
| SCHEMBL1506557 | 0.83 | DRD1 (0.62) | DRD1DRD2DRD5DRD3DRD4 | |
| SCHEMBL31028084 | 0.83 | DRD1 (0.62) | DRD1DRD2DRD5DRD3DRD4 | |
| SCHEMBL227363 | 0.82 | CYP1A2 (0.60) | DRD1DRD2DRD5DRD3DRD4 | |
| Sulfurous Acid SCHEMBL6400949 | 0.82 | CYP1A2 (0.47) | DRD1DRD2DRD5DRD3DRD4 | |
| SCHEMBL7510392 | 0.79 | METAP1 (0.54) | METAP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1553170-B1 | NOVEL CARBONYL REDUCTASE, GENE THEREOF AND METHOD OF USING THE SAME | KANEKA CORP (JP) | 2012-06-27 | — | — | EP | claimed |
| US-7531329-B2 | Carbonyl reductase, gene thereof and method of using the same | KANEKA CORPORATION (JP) | 2009-05-12 | — | — | US | claimed |
| US-20070178565-A1 | Novel carbonyl reductase, gene thereof and method of using the same | KANEKA CORPORATION | 2007-08-02 | — | — | US | claimed |
| US-20060035357-A1 | Novel carbonyl reductase, gene thereof and method of using the same | KANEKA CORPORATION (JP) | 2006-02-16 | — | — | US | claimed |
| WO-2020212543-A1 | COMPOUNDS FOR OPTICALLY ACTIVE DEVICES | MERCK PATENT GMBH (DE) | 2020-10-22 | — | — | WO | disclosed |
| WO-2015038868-A1 | FUSED BICYCLIC 2,4-DIAMINOPYRIMIDINE DERIVATIVES | CEPHALON, INC. (US) | 2015-03-19 | — | — | WO | disclosed |
| US-8779154-B2 | Fused ring compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. | 2014-07-15 | — | — | US | disclosed |
| US-8779154-B2 | Fused ring compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. | 2014-07-15 | — | — | US | disclosed |
| US-8779154-B2 | Fused ring compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. | 2014-07-15 | — | — | US | disclosed |
| EP-1553170-B1 | NOVEL CARBONYL REDUCTASE, GENE THEREOF AND METHOD OF USING THE SAME | KANEKA CORP (JP) | 2012-06-27 | — | — | EP | disclosed |
| EP-2086983-A2 | FUSED RING COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2009-08-12 | — | — | EP | disclosed |
| US-7531329-B2 | Carbonyl reductase, gene thereof and method of using the same | KANEKA CORPORATION (JP) | 2009-05-12 | — | — | US | disclosed |
| US-20020006956-A1 | Propanolamine derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-01-17 | — | — | US | disclosed |
| EP-1070046-A1 | PROPANOLAMINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-01-24 | — | — | EP | disclosed |
| EP-0976720-A1 | PROPANOLAMINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-02-02 | — | — | EP | disclosed |
| WO-1999051564-A1 | PROPANOLAMINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-10-14 | — | — | WO | disclosed |
| EP-0583485-B1 | ETHANOLAMINE DERIVATIVES HAVING SYMPATHOMIMETIC AND ANTI-POLLAKIURIA ACTIVITIES | FUJISAWA PHARMACEUTICAL CO (JP) | 1997-08-13 | — | — | EP | disclosed |
| US-5387710-A | Ethanolamine derivatives having sympathomimetic and anti-pollakiuria activities | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-02-07 | — | — | US | disclosed |
| EP-0583485-A1 | ETHANOLAMINE DERIVATIVES HAVING SYMPATHOMIMETIC AND ANTI-POLLAKIURIA ACTIVITIES. | FUJISAWA PHARMACEUTICAL CO (JP) | 1994-02-23 | — | — | EP | disclosed |
| WO-1993015041-A1 | ETHANOLAMINE DERIVATIVES HAVING SYMPATHOMIMETIC AND ANTI-POLLAKIURIA ACTIVITIES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070178565-A1 | Novel carbonyl reductase, gene thereof and method of using the same | PYCR1, CBR3, CBR1 | DRD1 2439/4885DRD2 3670/4885DRD5 2043/4885 |
| US-20020006956-A1 | Propanolamine derivatives | PNLIP, ADRB1, FABP2 | DRD1 167/4885DRD2 115/4885DRD5 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.